Chemistry Rx Compounding and Specialty Pharmacy的动态

【Quasi-Static, Poiseuille Flow of Analgesics from an Elastomeric Pump: Theoretical Determination of Infusion Times and Toxicity Conditions】 Full article: https://lnkd.in/gGNxke3n (Authored by Clare B. Lipscombe, et al., from Vanderbilt University Medical Center (USA), etc.) The rate of infusion is a critical component of optimizing the delivery of analgesics and other medications. #Elastomeric_pumps provide caretakers and patients with a reliable, mobile infusion system that can be used for patients receiving intravenous chemotherapy, antibiotics, and post-operative analgesia. In this paper, we propose a quasi-static model for laminar flow from the elastic sphere of an elastomeric pump into a tube delivering analgesics or other medicines to a blood vessel, analyzes its flow rates, determines its toxicity conditions, and otherwise improves its operation. #Infusion_Therapy #BioFluids #Medical_Devices #Antibiotic_Delivery #Analgesic_Delivery

Fall into proven results! ?? With 1.6M cases worldwide, and trusted in over 50 countries, BENEV Exosomes provide both efficacy and safety you can rely on. Clinically studied and backed by extensive research, this advanced solution offers a trusted way to enhance post-treatment outcomes. #benevexosomes #exosomeregenerativecomplex #erc #erc+ #exosometreatment #benevskinscience #benev #benefiteveryone *EXOSOME Disclaimer: BENEV Exosome products powered by Exo-SCRT? are post care “topical use” cosmetic solutions. The isolated and purified exosomes in both products have been accepted by the PCPC, and International Cosmetic Ingredient Nomenclature Committee (INC), and the name ‘Human Adipose Stromal Cell Exosomes’ was given and published in the International Cosmetic Ingredient Dictionary and Handbook, known as INCI book. There are at this time no other cosmetic INCI name(s) assigned to exosome products in the market prior to this accomplishment. These products are not drug products. They are not intended to prevent, treat or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously. Exosome Regenerative Complex+: For Skin & Scalp, Professional Use, Immediate Post-Treatment

Fall into proven results! ?? With 1.6M cases worldwide, and trusted in over 50 countries, BENEV Exosomes provide both efficacy and safety you can rely on. Clinically studied and backed by extensive research, this advanced solution offers a trusted way to enhance post-treatment outcomes. #benevexosomes #exosomeregenerativecomplex #erc #erc+ #exosometreatment #benevskinscience #benev #benefiteveryone *EXOSOME Disclaimer: BENEV Exosome products powered by Exo-SCRT? are post care “topical use” cosmetic solutions. The isolated and purified exosomes in both products have been accepted by the PCPC, and International Cosmetic Ingredient Nomenclature Committee (INC), and the name ‘Human Adipose Stromal Cell Exosomes’ was given and published in the International Cosmetic Ingredient Dictionary and Handbook, known as INCI book. There are at this time no other cosmetic INCI name(s) assigned to exosome products in the market prior to this accomplishment. These products are not drug products. They are not intended to prevent, treat or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously. Exosome Regenerative Complex+: For Skin & Scalp, Professional Use, Immediate Post-Treatment

Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show. https://lnkd.in/eDzPD4-H

Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show. https://lnkd.in/ehadfk3j

Do you know the difference? ???? Let us know in the comments below! ??: @breaanawheeler_np #benevexosomes #exosomeregenerativecomplex #erc #erc+ #benevskinscience #exosome #exosometechnology #exosometreatment *EXOSOME Disclaimer: BENEV Exosome products powered by Exo-SCRT? are post care “topical use” cosmetic solutions. The isolated and purified exosomes in both products have been accepted by the PCPC, and International Cosmetic Ingredient Nomenclature Committee (INC), and the name ‘Human Adipose Stromal Cell Exosomes’ was given and published in the International Cosmetic Ingredient Dictionary and Handbook, known as INCI book. There are at this time no other cosmetic INCI name(s) assigned to exosome products in the market prior to this accomplishment. These products are not drug products. They are not intended to prevent, treat or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously. Exosome Regenerative Complex+: For Skin & Scalp, Professional Use, Immediate Post-Treatment

Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show. https://lnkd.in/ehadfk3j

Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show. https://lnkd.in/ehadfk3j

Do you know the difference? Let us know in the comments below! #benevexosomes #exosometechnology #exosometreatment *EXOSOME Disclaimer: BENEV Exosome products powered by Exo-SCRT? are post care “topical use” cosmetic solutions. The isolated and purified exosomes in both products have been accepted by the PCPC, and International Cosmetic Ingredient Nomenclature Committee (INC), and the name ‘Human Adipose Stromal Cell Exosomes’ was given and published in the International Cosmetic Ingredient Dictionary and Handbook, known as INCI book. There are at this time no other cosmetic INCI name(s) assigned to exosome products in the market prior to this accomplishment. These products are not drug products. They are not intended to prevent, treat or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously. Exosome Regenerative Complex+: For Skin & Scalp, Professional Use, Immediate Post-Treatment

Following the FDA decision on Suzetrigine for the treatment of moderate-to-severe pain, don’t miss our blog on the opportunities and challenges as innovators in the non-addictive prescription medicine area. Read more here: https://bit.ly/42F16rV